Fareva to grow its newly acquired biomanufacturing capabilities
A leading third-party manufacturer in the small molecule active pharmaceutical ingredient (API) and finished formulation industry, Fareva entered the biologics CDMO sector last year, subsequently acquiring an oncology injectable facility in Pau, Southwestern France, and a monoclonal antibody (mAb) production site equipped with single-use technologies up to the 2,000 L scale in Saint-Julien-en-Genevois along the French-Swiss border, in November.
Fareva’s spokeswoman, Marie Wicart, stated that although the Pau facility was the primary objective of the acquisitions, “the acquisition of the monoclonal antibody site of Saint-Julien-en-Genevois is an interesting opportunity,” and “a first step” in the third-party biomanufacturing space.
The mAB plant, now renamed GTP Biologics, is expected to receive “a major investment” for expansion according to Sebastien Poncet, VP of Strategic licensing, who added that GTP Biologics intends to be a one-stop solution for drug makers through upstream anddownstream production, nano-encapsulation, and fill & finish services. Over 20 stable cell lines (CHO, NS0) with mAbs titers over 5g/L in non-optimized process have already been delivered by the upstream production unit, and five projects have been developed to clinical phases by the facility’s team.